The acute brain response to levodopa heralds dyskinesias in Parkinson disease

Annals of Neurology

Volumn 75, Issue 6, 2014, Pages 829-836

  Herz, Damian M ^a,b   Haagensen, Brian N ^a   Christensen, Mark S ^a,c   Madsen, Kristoffer H ^a,d   Rowe, James B ^e,f,g   Løkkegaard, Annemette ^b   Siebner, Hartwig R ^a,b,h  

^a HVIDOVRE HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; BLOOD OXYGENATION; BOLD SIGNAL; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DYSKINESIA; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HEAD MOVEMENT; HUMAN; MALE; NEUROIMAGING; NOISE; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; WHITE MATTER;

AGED; ANTIPARKINSON AGENTS; BRAIN; BRAIN MAPPING; DECISION MAKING; DYSKINESIA, DRUG-INDUCED; FEMALE; HEAD MOVEMENTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEVODOPA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; REACTION TIME; TIME FACTORS;

EID: 84903732818     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24138     Document Type: Article

References (42)

1. Hauser RA,. Levodopa: past, present, and future. Eur Neurol 2009; 62: 1-8.
2. Fahn S,. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann Neurol 2008; 64 (suppl 2): S56-S64.
3. Ahlskog JE, Muenter MD,. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
4. Carta M, Carlsson T, Kirik D, Bjorklund A,. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130 (pt 7): 1819-1833.
5. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49: 298-303.
6. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009; 72: 1211-1216.
7. Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9: 1106-1117.
8. Jenner P,. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665-677.
9. Cerasa A, Pugliese P, Messina D, et al. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov Disord 2012; 27: 364-371.
10. Buck K, Voehringer P, Ferger B,. Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats. Neuroscience 2010; 166: 355-358.
11. Carta M, Lindgren HS, Lundblad M, et al. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 2006; 96: 1718-1727.
12. Brooks DJ, Piccini P, Turjanski N, Samuel M,. Neuroimaging of dyskinesia. Ann Neurol 2000; 47 (4 suppl 1): S154-S158; discussion S158-S159.
13. Nutt JG, Holford NH,. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561-573.
14. Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990; 13: 19-28.
15. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ,. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
16. Macoveanu J, Rowe JB, Hornboll B, et al. Playing it safe but losing anyway-serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. Eur Neuropsychopharmacol 2013; 23: 919-930.
17. Luh WM, Wong EC, Bandettini PA, Hyde JS,. QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med 1999; 41: 1246-1254.
18. Gunther M, Oshio K, Feinberg DA,. Single-shot 3D imaging techniques improve arterial spin labeling perfusion measurements. Magn Reson Med 2005; 54: 491-498.
19. Groves AR, Chappell MA, Woolrich MW,. Combined spatial and non-spatial prior for inference on MRI time-series. Neuroimage 2009; 45: 795-809.
20. Friston KJ, Williams S, Howard R, et al. Movement-related effects in fMRI time-series. Magn Reson Med 1996; 35: 346-355.
21. Lund TE, Madsen KH, Sidaros K, et al. Non-white noise in fMRI: does modelling have an impact? Neuroimage 2006; 29: 54-66.
22. Herz DM, Eickhoff SB, Lokkegaard A, Siebner HR,. Functional neuroimaging of motor control in parkinson's disease: A meta-analysis. Hum Brain Mapp. 2013. doi: 10.1002/hbm.22397. [EPub ahead of print].
23. Cenci MA, Lundblad M,. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006; 99: 381-392.
24. Di Martino A, Scheres A, Margulies DS, et al. Functional connectivity of human striatum: a resting state FMRI study. Cereb Cortex 2008; 18: 2735-2747.
25. Cortes C, Vapnik V,. Support-vector networks. Machine Learning 1995; 20: 273-297.
26. Nejad AB, Madsen KH, Ebdrup BH, et al. Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. Int J Neuropsychopharmacol 2013; 16: 1195-1204.
27. Bartzokis G, Mintz J, Sultzer D, et al. In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol 1994; 15: 1129-1138.
28. Kish SJ, Shannak K, Hornykiewicz O,. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876-880.
29. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127 (pt 12): 2747-2754.
30. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612-1617.
31. Rascol O, Sabatini U, Brefel C, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 1998; 121 (pt 3): 527-533.
32. Graybiel AM,. Habits, rituals, and the evaluative brain. Annu Rev Neurosci 2008; 31: 359-387.
33. Schmidt R, Leventhal DK, Mallet N, et al. Canceling actions involves a race between basal ganglia pathways. Nat Neurosci 2013; 16: 1118-1124.
34. Alexander GE, DeLong MR, Strick PL,. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
35. Fried I, Mukamel R, Kreiman G,. Internally generated preactivation of single neurons in human medial frontal cortex predicts volition. Neuron 2011; 69: 548-562.
36. Lau HC, Rogers RD, Haggard P, Passingham RE,. Attention to intention. Science 2004; 303: 1208-1210.
37. Wolpe N, Moore JW, Rae CL, et al. The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome. Brain 2014; 137 (pt 1): 208-220.
38. Rowe J, Stephan KE, Friston K, et al. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain 2002; 125 (pt 2): 276-289.
39. Rowe JB, Hughes LE, Barker RA, Owen AM,. Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage 2010; 52: 1015-1026.
40. Forstmann BU, Dutilh G, Brown S, et al. Striatum and pre-SMA facilitate decision-making under time pressure. Proc Natl Acad Sci U S A 2008; 105: 17538-17542.
41. Brusa L, Versace V, Koch G, et al. Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease. Clin Neurophysiol 2006; 117: 1917-1921.
42. Koch G, Brusa L, Caltagirone C, et al. rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology 2005; 65: 623-625.